Table 11.
Test 4: Sensitivity Analysis Olanzapine Versus Risperidone: Changing CATIE Relapse Risk Ratios to Achieve Desired ICER Result
| ICER | ||
| RIS/OLZ Ratio | OLZ | RIS |
| 1.55 (Base Case)* | Dominant | - |
| 1.54 | Cost-Neutral | |
| 0.70 | Effectiveness-Neutral | |
*Base case ratio from CATIE Phase 1 [23] which reported hospitalization risk ratios normalized to 1 person year of exposure: RIS = 0.45, OLZ = 0.29, and RIS/OLZ = 1.55.
ICER = incremental cost-effectiveness ratio; RIS = risperidone; OLZ = olanzapine